Inventor · disambiguated record
Kin-Ming Lo
Also filed as: LO KIN-MING
41 granted patents·18 pending applications·2,236 citations·filing 1991–2022
99Inventor score
Files withMERCK PATENT GMBH26EMD LEXIGEN RES CT CORP12FUJI IMMUNOPHARMACEUTICALS COR3GILLIES STEPHEN D3LO KIN-MING3
Top patents by PatentIndex Score
59 records- 0199US9676863B2Targeted TGFβ inhibitorsMERCK PATENT GMBH·Filed 2015·Granted Jun 13, 2017·78 cites·6 claims
- 0299US6617135B1Multiple cytokine protein complexesEMD LEXIGEN RES CT CORP·Filed 2000·Granted Sep 9, 2003·211 cites·17 claims
- 0398US7186804B2IL-2 fusion proteins with modulated selectivityEMD LEXIGEN RES CT CORP·Filed 2002·Granted Mar 6, 2007·140 cites·23 claims
- 0498US7148321B2Expression technology for proteins containing a hybrid isotype antibody moietyEMD LEXIGEN RES CT CORP·Filed 2002·Granted Dec 12, 2006·114 cites·10 claims
- 0598US7091321B2Enhancing the circulating half-life of antibody-based fusion proteinsEMD LEXIGEN RES CT CORP·Filed 2001·Granted Aug 15, 2006·133 cites·31 claims
- 0697US7888071B2DNA encoding IL-2 fusion proteins with modulated selectivityMERCK PATENT GMBH·Filed 2008·Granted Feb 15, 2011·48 cites·26 claims
- 0797US7790415B2Enhancing the circulating half-life of antibody-based fusion proteinsMERCK PATENT GMBH·Filed 2009·Granted Sep 7, 2010·43 cites·42 claims
- 0897US7067110B1Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigensEMD LEXIGEN RES CT CORP·Filed 2000·Granted Jun 27, 2006·110 cites·25 claims
- 0997US5726044AExpression and export technology of proteins as immunofusinsFUJI IMMUNOPHARMACEUTICALS COR·Filed 1995·Granted Mar 10, 1998·259 cites·8 claims
- 1097US5541087AExpression and export technology of proteins as immunofusinsFUJI IMMUNOPHARMACEUTICALS COR·Filed 1994·Granted Jul 30, 1996·463 cites·12 claims
- 1196US7670595B2Fc-interferon-beta fusion proteinsMERCK PATENT GMBH·Filed 2005·Granted Mar 2, 2010·54 cites·16 claims
- 1296US7507406B2Enhancing the circulating half-life of antibody-based fusion proteinsEMD SERONO RES CT INC·Filed 2005·Granted Mar 24, 2009·49 cites·20 claims
- 1396US7169904B2Immunocytokine sequences and uses thereofEMD LEXIGEN RES CT CORP·Filed 2003·Granted Jan 30, 2007·46 cites·5 claims
- 1496US6838260B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationEMD LEXIGEN RES CT CORP·Filed 2001·Granted Jan 4, 2005·78 cites·8 claims
- 1595US8066994B2Proteins comprising an IgG2 domainGILLIES STEPHEN D·Filed 2006·Granted Nov 29, 2011·25 cites·13 claims
- 1695US7955590B2Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigensMERCK PATENT GMBH·Filed 2005·Granted Jun 7, 2011·40 cites·68 claims
- 1795US7767405B2Immunocytokine sequences and uses thereofMERCK PATENT GMBH·Filed 2006·Granted Aug 3, 2010·25 cites·4 claims
- 1895US7462350B2Cancer treatments including administering IL-2 fusion proteins with modulated selectivityEMD SERONO RES CT INC·Filed 2006·Granted Dec 9, 2008·34 cites·4 claims
- 1994US7226998B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationEMD LEXIGEN RES CT CORP·Filed 2004·Granted Jun 5, 2007·35 cites·8 claims
- 2094US7141651B2Multiple cytokine protein complexesEMD LEXIGEN RES CT CORP·Filed 2003·Granted Nov 28, 2006·50 cites·29 claims
- 2194US6969517B2Recombinant tumor specific antibody and use thereofEMD LEXIGEN RES CT CORP·Filed 2002·Granted Nov 29, 2005·54 cites·5 claims
- 2293US7576193B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationMERCK PATENT GMBH·Filed 2007·Granted Aug 18, 2009·11 cites·8 claims
- 2392US7582288B2Methods of targeting multiple cytokinesMERCK PATENT GMBH·Filed 2006·Granted Sep 1, 2009·14 cites·6 claims
- 2490US8043608B2Methods of using Fc-cytokine fusion proteinsMERCK PATENT GMBH·Filed 2009·Granted Oct 25, 2011·13 cites·6 claims
- 2589US8562986B2Engineered anti-alpha V-integrin hybrid antibodiesGOODMAN SIMON·Filed 2008·Granted Oct 22, 2013·26 cites·36 claims
- 2689US7879319B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationMERCK PATENT GMBH·Filed 2009·Granted Feb 1, 2011·8 cites·3 claims
- 2789US7872107B2Interleukin-12p40 variants with improved stabilityMERCK PATENT GMBH·Filed 2006·Granted Jan 18, 2011·15 cites·29 claims
- 2886US7459538B2Recombinant tumor specific antibody and use thereofMERCK PATENT GMBH·Filed 2005·Granted Dec 2, 2008·7 cites·16 claims
- 2985US7803618B2Recombinant tumor specific antibody and use thereofMERCK PATENT GMBH·Filed 2008·Granted Sep 28, 2010·2 cites·19 claims
- 3083US8206718B2Expression and export of angiogenesis inhibitors as immunofusinsLO KIN-MING·Filed 2006·Granted Jun 26, 2012·5 cites·4 claims
- 3183US8188248B2Nucleic acids encoding interleukin-12P40 variants with improved stabilityWEBSTER GORDON D·Filed 2010·Granted May 29, 2012·8 cites·32 claims
- 3282US9029330B2Methods of treating cancer using interleukin-12p40 variants having improved stabilityWEBSTER GORDON D·Filed 2012·Granted May 12, 2015·7 cites·26 claims
- 3381US8557232B2Stabilization of Fc-interferon-beta fusion proteinsGILLIES STEPHEN D·Filed 2009·Granted Oct 15, 2013·5 cites·14 claims
- 3480US8470991B2Immunocytokine sequences and uses thereofGILLIES STEPHEN D·Filed 2010·Granted Jun 25, 2013·2 cites·1 claims
- 3579US8703908B2Expression and export of angiogenesis inhibitors as immunofusinsLO KIN-MING·Filed 2012·Granted Apr 22, 2014·3 cites·17 claims
- 3679US2023056881A1TARGETED TGFß INHIBITIONMERCK PATENT GMBH·Filed 2022·Application pending·0 cites
- 3773US8907066B2Antibody fusion proteins with a modified FcRn binding siteLO KIN-MING·Filed 2010·Granted Dec 9, 2014·2 cites·9 claims
- 3872US11021694B2SIRP-α immunoglobulin fusion proteinsMERCK PATENT GMBH·Filed 2015·Granted Jun 1, 2021·2 cites·20 claims
- 3970US8420087B2Interleukin-12 targeted to oncofoetal fibronectinGILLIES STEPHEN·Filed 2005·Granted Apr 16, 2013·3 cites·10 claims
- 4067US11370819B2Targeted TGFβ inhibitionMERCK PATENT GMBH·Filed 2019·Granted Jun 28, 2022·0 cites·20 claims
- 4164US2022017621A1Combination Therapy for CancerMERCK PATENT GMBH·Filed 2021·Application pending·0 cites
- 4263US2009088561A1Enhancing the circulating half-life of antibody-based fusion proteinsMERCK PATENT GMBH·Filed 2008·Application pending·0 cites
- 4358US2018002436A1TARGETED TGFß INHIBITIONMERCK PATENT GMBH·Filed 2017·Application pending·0 cites
- 4457US2006194952A1Enhancing the circulating half-life of antibody-based fusion proteinsEMD LEXIGEN RES CT CORP·Filed 2006·Application pending·0 cites
- 4556US2005202538A1Fc-erythropoietin fusion protein with improved pharmacokineticsMERCK PATENT GMBH·Filed 2004·Application pending·0 cites
- 4656US2014005361A1FC-Interferon-Beta Fusion ProteinsMERCK PATENT GMBH·Filed 2013·Application pending·0 cites
- 4755US2008025947A1Methods for enhancing the efficacy of IL-2 mediated immune responsesMERCK PATENT GMBH·Filed 2007·Application pending·0 cites
- 4854US2015274797A1Antibody Fusion Proteins with a Modified FcRn Binding SiteMERCK PATENT GMBH·Filed 2014·Application pending·0 cites
- 4953US2005042729A1Expression and export of interferon-alpha proteins as Fc fusion proteinsEMD LEXIGEN RES CT CORP·Filed 2004·Application pending·0 cites
- 5052US2003139365A1Expression and export of angiogenesis inhibitors as immunofusinsFiled 2002·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →